Headlines

USTR says they have commenced a Section 301 probe of Germany regarding pharmaceuticals, to determine whether persistent underpayment for innovative pharmaceutical products by Germany is unreasonable or discriminatory

Newsquawk Staff ·

  • USTR will hold a hearing in connection with these investigations on September 22nd, 2026.

Potential means/tools that could follow

  • supplemental discounts in exchange for confidentiality of negotiated prices; and
  • mandatory variable rate rebates.

USTR Greer

  • "I am particularly concerned with news that Germany is fast-tracking legislation that would further reduce its spending on innovative pharmaceuticals"

Sources

Related headlines